National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tivozanib (Fotivda®) is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.

NCPE Assessment Process Complete
Rapid review commissioned 09/01/2019
Rapid review completed 24/01/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tivozanib compared with the current standard of care.